Literature DB >> 11127251

Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study.

C P Thakur1, T P Kanyok, A K Pandey, G P Sinha, C Messick, P Olliaro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11127251     DOI： 10.1016/s0035-9203(00)90131-7

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN： 0035-9203            Impact factor:   2.184


× No keyword cloud information.
  21 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Recent Developments in Leishmaniasis: Epidemiology, Diagnosis, and Treatment.

Authors:  Jonathan Berman
Journal:  Curr Infect Dis Rep       Date:  2005-01       Impact factor: 3.725

Review 3.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

4.  Alternative drug treatments for visceral leishmaniasis: miltefosine.

Authors:  Mary E Wilson
Journal:  Curr Infect Dis Rep       Date:  2008-03       Impact factor: 3.725

Review 5.  Kinetoplastids: related protozoan pathogens, different diseases.

Authors:  Ken Stuart; Reto Brun; Simon Croft; Alan Fairlamb; Ricardo E Gürtler; Jim McKerrow; Steve Reed; Rick Tarleton
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

Review 6.  [Kala azar. Rare import and significant differential diagnosis].

Authors:  H Sudeck
Journal:  Internist (Berl)       Date:  2006-08       Impact factor: 0.743

7.  Paromomycin: uptake and resistance in Leishmania donovani.

Authors:  Anupam Jhingran; Bhavna Chawla; Shailendra Saxena; Michael Peter Barrett; Rentala Madhubala
Journal:  Mol Biochem Parasitol       Date:  2008-12-25       Impact factor: 1.759

8.  Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.

Authors:  Jyotsna Mishra; Rentala Madhubala; Sarman Singh
Journal:  Parasitol Res       Date:  2012-12-18       Impact factor: 2.289

9.  Water-soluble polymer-drug conjugates for combination chemotherapy against visceral leishmaniasis.

Authors:  Salvatore Nicoletti; Karin Seifert; Ian H Gilbert
Journal:  Bioorg Med Chem       Date:  2010-03-02       Impact factor: 3.641

10.  Visceral leishmaniasis relapse in Southern Sudan (1999-2007): a retrospective study of risk factors and trends.

Authors:  Stanislaw Gorski; Simon M Collin; Koert Ritmeijer; Kees Keus; Francis Gatluak; Marius Mueller; Robert N Davidson
Journal:  PLoS Negl Trop Dis       Date:  2010-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.